Product Description
OM-RCA-01 is an original innovative targeting drug focused on blocking FGFR1. OM-RCA-01 binds to the extracellular part of FGFR1. The main mechanism of action is blocking the activation processes of FGFR1. In studies, OM-RCA-01 was found to be a high-affinity and specific to FGFR1 antibody, inhibiting the phosphorylation of the receptor and the subsequent intracellular cascade. The amount of human protein in the structure of the humanized antibody is 92.9%. (Sourced from: https://clinicaltrials.gov/study/NCT07292168)
Mechanisms of Action: FGFR1 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kidney Cancer Research Bureau
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Prostate Cancer|Acrocephalosyndactylia|Kidney Cancer|Head and Neck Cancer|Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07292168 |
TAGNOT | P2 |
Active, not recruiting |
Renal Cell Carcinoma|Breast Cancer|Head and Neck Cancer|Prostate Cancer|Kidney Cancer|Acrocephalosyndactylia|Non-Small-Cell Lung Cancer |
2027-01-01 |
2025-12-19 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|